2-(2-苯基甲氧基苯基)乙酰氯 | 115439-34-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(2-苯基甲氧基苯基)乙酰氯
• 英文名称: (2-benzyloxy-phenyl)-acetyl chloride
• 英文别名: [2-(Benzyloxy)phenyl]acetyl chloride；2-(2-phenylmethoxyphenyl)acetyl chloride
• CAS: 115439-34-4
• 化学式: C₁₅H₁₃ClO₂
• 分子量: 260.72
• InChiKey: FRSJSWUPCYJSKL-UHFFFAOYSA-N

物化性质

• 沸点：
  376.7±30.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-苯基甲氧基苯基)乙酰氯 在 sodium azide 作用下， 以 氯仿 、 水 、 丙酮 为溶剂， 反应 1.0h， 生成 2-benzyloxybenzyl isocyanate
  参考文献：
  名称：

  Orally active .beta.-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones

  摘要：

  A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1-[[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally active inhibitor of human leukocyte elastase (HLE). Analogs of 2 with different substituents on the urea N were synthesized and evaluated for their activity in vitro against HLE as well as in vivo in a hamster lung hemorrhage model. Compounds with a methyl or a methoxy group in the para position of the benzene ring were very potent in both assays. The results are discussed on the basis of the proposed model for the binding of this class of inhibitors to HLE and a possible mechanism of inhibition is presented.

  DOI：

  10.1021/jm00099a003
• 作为产物：
  描述：

  4-苄氧基苯乙酸 在 氯化亚砜 作用下， 生成 2-(2-苯基甲氧基苯基)乙酰氯
  参考文献：
  名称：

  Synthesis and in vitro antitumor activity of asperphenamate derivatives as autophagy inducer

  摘要：

  In an effort to improve the aqueous solubility and the antitumor activity of natural product asperphenamate, we have designed and synthesized three series of asperphenamate derivatives, including series I (simplifying molecular skeleton series), series II (introducing a hydroxyl group to A-phenyl ring series) and series III (disrupting molecular planarity series). All derivatives have displayed a significantly increased solubility compared with asperphenamate. Their growth inhibitory activities in vitro were screened by the standard MTT method in MCF-7, HeLa, and BEL-7402 cell lines. With the exception of the derivatives in series I, most of derivatives in series II and series III showed growth inhibitory activity. Among all derivatives, IM23b in series III showed the greatest potency in human breast cancer MCF-7 cells. The cellular potency of IM23b was approximately 1.5-fold more potent than that of cisplatin. The mechanism of cell death induced by IM23b in human breast cancer MCF-7 cells was further investigated. We concluded that the cell death was induced by autophagy instead of apoptosis or cell cycle arrest. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.101

文献信息

• [1,2,4]TRIAZOLO [1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS
  申请人：Casale Elena

  公开号：US20120184546A1

  公开（公告）日：2012-07-19

  The present invention relates to [1,2,4]triazolo[1,5-c]pyrimidine derivatives of formula (I) which inhibit the activity of Heat Shock Protein Hsp90. The compounds of the invention are therefore useful in treating proliferative diseases such as cancer and neurodegenerative diseases. The present invention also provides processes for preparing these compounds, methods of treating diseases and the pharmaceutical compositions comprising these compounds.

  本发明涉及式(I)的[1,2,4]三唑并[1,5-c]嘧啶衍生物，其抑制热休克蛋白Hsp90的活性。因此，本发明的化合物在治疗癌症和神经退行性疾病等增殖性疾病方面是有用的。本发明还提供了制备这些化合物的方法、治疗疾病的方法以及包含这些化合物的药物组合物。
• 2- and 2,5-substituted phenylketoenols
  申请人：Bayer Aktiengesellschaft

  公开号：US06359151B2

  公开（公告）日：2002-03-19

  The invention relates to novel phenyl-substituted cyclic ketoenols of the formula (I) in which Het represents one of the groups  in which A, B, D, G, X and Z are each as defined in the description, to a plurality of processes and intermediates for their preparation, and to their use as pesticides.

  该发明涉及公式(I)中的新型苯基取代的环状酮烯醇，其中Het代表其中一种基团，在其中A、B、D、G、X和Z各自如描述中定义的多种过程和中间体的制备，以及它们作为杀虫剂的用途。
• Stereoselective synthesis of the dihydrobenzo[b]furan segments of the ephedradine alkaloids
  作者：Raymond Baker、Nigel G. Cooke、Guy R. Humphrey、Stanley H. B. Wright、Jordan Hirshfield

  DOI：10.1039/c39870001102

  日期：——

  Syntheses of dihydrobenzofuran derivatives have involved formation of phenol substituted β-hydroxy esters by an aldol reaction followed by Lewis-acid-catalysed intramolecular cyclisation as key steps; the use of chiral oxazolidinones in the aldol reaction has formed the basis of enantionspecific syntheses.

  二氢苯并呋喃衍生物的合成涉及通过醛醇缩合反应形成酚取代的β-羟基酯，然后是路易斯酸催化的分子内环化反应。手性恶唑烷酮在醛醇缩合反应中的使用已形成对映体特异性合成的基础。
• Compounds and methods for modulation of estrogen receptors
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US20040082575A1

  公开（公告）日：2004-04-29

  Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-&bgr;. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

  本发明揭示了调节雌激素受体（ER）的化合物，以及包含这些化合物的药物组合物。在一个具体的实施例中，这些化合物对ER-β比ER-α具有选择性。揭示了在表达具有偏好ER-β的细胞和/或组织中调节ER-β的方法，包括治疗雌激素相关疾病的方法，例如乳腺癌、睾丸癌、骨质疏松症、子宫内膜异位症、心血管疾病、高胆固醇血症、前列腺增生、前列腺癌、肥胖、潮热、皮肤影响、情绪波动、记忆力下降、尿失禁、脱发、白内障、自然激素失衡以及与环境化学物质暴露相关的不良生殖影响。
• [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS
  申请人：Casale Elena

  公开号：US20140045836A1

  公开（公告）日：2014-02-13

  The present invention relates to [1,2,4]triazolo[1,5-c]pyrimidine derivatives which inhibit the activity of Heat Shock Protein Hsp90. The compounds of the invention are therefore useful in treating proliferative diseases such as cancer and neurodegenerative diseases. The present invention also provides processes for preparing these compounds, methods of treating diseases and the pharmaceutical compositions comprising these compounds.

  本发明涉及[1,2,4]三唑并[1,5-c]嘧啶衍生物，其抑制热休克蛋白Hsp90的活性。因此，该发明的化合物在治疗癌症和神经退行性疾病等增殖性疾病方面具有用途。本发明还提供了制备这些化合物的方法，治疗疾病的方法以及包含这些化合物的制药组合物。